OncoMatch/Clinical Trials/NCT07148050
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Is NCT07148050 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SC-CAR.GPC3xIL15.21 CAR T cells for solid tumor (excluding cns).
Treatment: SC-CAR.GPC3xIL15.21 CAR T cells — This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21 as well as the inducible caspase 9 (iC9) suicide gene (SC-CAR.GPC3xIL15.21 T cells). A child or young adult meeting all eligibility criteria and meeting none of the exclusion criteria will have a blood sample collected, which will be used to bioengineer the CAR T cells targeting their tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Glioblastoma
Sarcoma
Rhabdomyosarcoma
Hepatocellular Carcinoma
Biomarker criteria
Required: GPC3 expression
Disease stage
Required: Stage BARCELONA LIVER CANCER STAGE A, BARCELONA LIVER CANCER STAGE B, BARCELONA LIVER CANCER STAGE C (Barcelona Liver Cancer)
Barcelona Liver Cancer Stage A, B or C
Prior therapy
Must have received: cytotoxic chemotherapy — up-front therapy and at least one salvage treatment cycle
Refractory or relapsed disease after treatment with up-front therapy and at least one salvage treatment cycle
Lab requirements
Blood counts
Adequate laboratory values
Kidney function
Adequate organ function
Liver function
Child-Pugh Turcotte Score <7
Cardiac function
No congestive heart failure (NYHA III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, myocardial infarction within 6 months, or history of myocarditis
Adequate organ function; Child-Pugh Turcotte Score <7; Adequate laboratory values; Congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, a myocardial infarction within 6 months prior to study entry or a history of myocarditis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Seattle Children's Hospital · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify